It is noteworthy that recent studies suggest that KRAS/BRAF mutations play critical roles in the subtyping and prognosis of ovarian tumors, pointing toward future directions for integrating radiomics with molecular biomarkers (34). This evidence concerns the gene BRAF and ovarian neoplasm.